skinny.

Latest / The Top Line

Forging the future of cell therapy: Bayer and BlueRock’s unique journey (Sponsored)

In this episode of The Top Line, Fierce Biotech’s Chris Hayden sat down with Dr. Juergen Eckhardt of Bayer and Dr. Seth Ettenberg of BlueRock Therapeutics to discuss an innovative partnership that’s reshaping how big pharma teams up with biotech startups. BlueRock, a wholly owned subsidiary of Bayer, operates with the independence of a small biotech while benefiting from Bayer’s global reach and infrastructure. The “arm’s-length” model gives BlueRock the agility to innovate while leveraging Bayer’s resources in manufacturing, clinical trials and…

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.